Proliferative Vitreoretinopathy (PVR) Therapeutics Pipeline Report 2016 – Review of 3 Companies & 6 Molecules – Research and Markets
DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "Proliferative Vitreoretinopathy (PVR) - Pipeline Review, H2 2016" report to their offering. Proliferative Vitreoretinopathy (PVR) pipeline therapeutics constitutes close to 6 molecules. Out of which approximately 5 molecules are developed by Companies and remaining by the Universities/Institutes. Our latest report Proliferative Vitreoretinopathy (PVR) - Pipeline Review, H2 2016, outlays comprehensive information on
